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Objective: To find a hematological parameter and the cut-off level for identification of non-
sickling hemoglobinopathies in pregnant women.
Materials and methods: Venous blood samples of 849 women with singleton pregnancies 
were collected at the first visit. All women who met inclusion criteria were examined for 
nonsickling hemoglobinopathy. On the basis of the sensitivity and the specificity of different 
cut-off levels for hematological parameters, we calculated the optimal clinically practicable 
parameter for screening of nonsickling hemoglobinopathies in pregnant women.
Results: On the basis of the sensitivity and the specificity, the best screening parameters for the 
identification of nonsickling hemoglobinopathies among nonanemic pregnant women are mean 
corpuscular volume (MCV) with cut-off 80 fL (Youden’s index 91.2%), mean corpuscular hemo-
globin (MCH) 27.5 pg (Youden’s index 90.7%), and microcytosis (MRC) 3% (Youden’s index 
90.2%). An analysis using receiver operating characteristic curves and the calculated Youden’s 
index showed that MCV 76 fL, MCH 24 pg, or MRC 10% are the best red blood cell indices 
for the screening of nonsickling hemoglobinopathy among anemic women with iron deficiency.
Conclusion: Our results suggest targeted screening for nonsickling hemoglobinopathies in 
nonanemic pregnant women with MCV 80 fL, MCH 27.5 pg, or MRC 3% and in anemic 
women with MCV 76 fL, MCH 24 pg, or MRC 10%.
Keywords: anemia, antenatal, hemoglobinopathy, pregnancy, screening, hemoglobin, hema-
tological parameters
Introduction
Hemoglobinopathies are among the most common inherited disorders worldwide.1,2 
Different policies for nonsickling hemoglobinopathies screening have been adapted in 
Europe. There are two strategies: one for high-prevalence areas, where all women are 
offered universal screening, and one for low-prevalence areas, where a more complex 
algorithm has been developed that is related to the red blood cell (RBC) indices results 
and the ethnic origin of women or her partner.3,4 Switzerland with the prevalence of 
0.92% belongs to the low-prevalence areas.5
Antenatal nonsickling hemoglobinopathy screening in low-prevalence areas, the 
so-called targeted antenatal nonsickling hemoglobinopathies screening, means a two-
step algorithm. The first step is a routine examination of RBC indices. However, to 
this day there are no generally used hematological parameters with a specific cut-off. 
Most laboratories use low mean corpuscular volume (MCV), low mean corpuscular 
hemoglobin (MCH), or high microcytosis (MRC) as criteria for screening, but the 
specific cut-off under which further investigation is carried out varies widely. Older 
studies quote an MCH 27 pg as a criterion,1,6 more recent ones quote MCH 26 pg7 
and MCV 78 fL,1 MCV 85 fL,6 or MCV 80 fL.7 Using these parameters we 
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cannot identify women with normal red cell indices (silent 
thalassemia and silent hemoglobinopathy) as well as women 
with sickle cell disorders (sickle cell trait and sickle cell 
disease). In women with positive RBC indices, laboratory 
diagnosis should be conducted.8 Any woman with a hemo-
globin variant whose partner has not been tested has been 
offered to have her partner tested for hemoglobinopathy.
As a result of the migration of people from countries 
with a high prevalence of hemoglobin disorders, laboratory 
diagnosis is of growing importance in North-West Europe. 
The aim of the early identification of women with nonsickling 
hemoglobinopathies is to optimize prenatal care.9 The 
purpose of this study is to determine a cut-off level of RBC 
indices for targeted nonsickling hemoglobinopathy screening 
in pregnant women.
Materials and methods
study population
A prospective cross-sectional study was carried out at the 
Department of Obstetrics and Gynecology, University Hospi-
tal Zurich. We examined 849 pregnant women with singleton 
pregnancies for their hematological status on the first visit to 
our antenatal clinic. The study was approved by the Human 
Research Ethics Committee at the Women’s Hospital in 
Zurich. Written and informed consent was obtained before 
the examination for the identification of nonsickling hemo-
globinopathy was conducted. Women who met inclusion 
criteria were tested for nonsickling hemoglobinopathy. 
Inclusion criteria for testing of nonsickling hemoglobin-
opathy were MCH 28 pg, MCV 81 fL, and MRC 3% 
in nonanemic women and MCH 26 pg, MCV 77 fL, 
and MRC 3% in anemic women. Women with sickle cell 
anemia were excluded from this analysis due to negative, ie, 
normal hematological parameters.
Hematology assessment
Hemoglobin (Hb), RBCs, hematocrit (HCT), MCV, and 
the percentage of microcytic and hypochromic erythrocytes 
(MRC and HRC) were measured using an ADVIA® hema-
tology analyzer system (Bayer Diagnostics, Leverkusen, 
Germany). MCH was automatically calculated from Hb and 
RBC. Serum ferritin was assessed by chemiluminescence 
immunoassay (ACS 190; Ciba/Corning Diagnostic Corp, 
Cleveland, OH, USA). C-reactive protein (CRP) was assessed 
in anemic women through immunoturbidimetry. A radioim-
munoassay was performed to determine vitamin B
12
 and folic 
acid. The hemoglobins were separated and processed by 
high-performance liquid chromatography (HPLC). Molecular 
analysis to identify the α-thalassemia was conducted. Meth-
ods used are described elsewhere.2
study criteria
According to current guidelines based on the recommenda-
tions of the Centers for Disease Control (USA), anemia in 
pregnancy is defined as an Hb value 110 g/L in both the first 
and third trimester and an Hb value 105 g/L in the second 
trimester.10 We diagnosed iron depletion if the serum ferritin 
was 20 µg/L.11,12 In all anemic women, the ascertainment 
of ferritin, CRP, folic acid, and vitamin B
12
 were conducted. 
Iron deficiency anemia (IDA) was defined as Hb 110 g/L 
and serum ferritin 20 µg/L. Anemia of other etiology was 
defined as Hb 110 g/L and ferritin 20 µg/L. This group 
included the following: vitamin B
12
 deficiency, folic acid 
deficiency, chronic inflammatory diseases (particularly HIV-
positive women, hepatitis B, lupus erythematosus, etc), liver 
or kidney disease, etc.
study design
We determined and compared the mean level of Hb, RBC, 
HCT, MCV, and MCH in all women; median of MRC and 
HRC in all women; and ferritin in women with inclusion 
criteria or with anemia. There were four groups of women: 
women with nonsickling hemoglobinopathy (group 1), 
women with IDA (group 2), women with anemia of other 
etiology (group 3), and nonanemic women (group 4). 
We determined sensitivity, specificity, positive predic-
tive value (PPV), negative predictive value (NPV), and 
Youden’s index of the following parameters in women with 
IDA: MCH with cut-off levels of 25 pg, 26 pg, 27 
pg, 27.5 pg, and 28 pg; MCV with cut-off levels 
of 75 fL, 76 fL, 77 fL, 78 fL, 79 fL, 80 fL, 
and 81 fL; and MRC with cut-off levels of 3%, 5%, 10%, 
and 15% in nonanemic women; and MCH with 
cut-off 23 pg, 24 pg, 25 pg, and 26 pg; MCV with 
cut-off levels of 74 fL, 75 fL, 76 fL, and 77 fL; 
and MRC with cut-off levels of 3%, 5%, 10%, 
and 15%. Receiver operating characteristic curves were 
used to construct a graphic representation of the relation 
between sensitivity and specificity of the inclusion hema-
tological parameters (MCV, MCH, and MRC).
statistical analysis
Statistical analysis was performed with Intercooled Stata 8.2 
for Windows (www.stata.com). The mean of hematological 
parameters (Hb, RBC, HCT, MCV, and MCH) and median 
of ferritin, HCR, and MRC and the standard deviation 
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within the range were calculated for each group. Specificity, 
sensitivity, PPV, NPV, and Youden’s index of different 
cut-off levels for MCV, MCH, and MRC in nonanemic 
pregnant women and women with IDA were calculated. The 
sensitivity was calculated as true positive/(true positive+false 
negative); the specificity was calculated as: true negative/
(true negative+false positive); PPV was calculated as: true 
positive/(true positive+false positive); NPV was calculated 
as: (true negative/true negative+false negative); Youden’s 
index was calculated as (sensitivity+specificity)–100.
Receiver operating characteristic curves were used to 
construct a graphic representation of the relation between 
sensitivity and specificity of the three hematological param-
eters (MCV, MCH, and MRC) with a highest sensitivity 
and specificity over all possible diagnostic cut-off values in 
nonanemic and anemic pregnant women.
Results
There were 849 women during enrolment and 829 women 
during the final analysis. Twenty women with MCH 25 pg, 
MCV 75 fL, and/or with anemia were excluded from the 
analysis due to loss to follow-up (9/20), poor compliance 
(8/20), or negative hematological screening parameters in 
women with sickle cell anemia (3/20).
The hematological data of the four groups are shown in 
Table 1. The mean hemoglobin in the group with nonsick-
ling hemoglobinopathies was 112±14 g/L. Only 12 women 
with nonsickling hemoglobinopathy suffered from anemia 
(12/24; 50%) and 6 had concomitant iron deficiency (6/24; 
25%). However, the median of ferritin in this group was 
50 µg/L and the median of hypochromic red cells for this 
group (7.6%) was higher than that in the group with IDA 
(2.8%). There was an increased erythrocyte count (mean 
RBC 4.8±0.5×106/µL) and increased MRC (median MRC 
18.6%) in this group of women. The mean gestational age 
on recruitment was 18±2 weeks.
The overall prevalence of nonsickling hemoglobin-
opathies was 3.3% (27/829). There were nine women with 
homozygous α-thalassemia and six with heterozygous 
α-thalassemia, one with homozygous β-thalassemia and 
six women with heterozygous β-thalassemia, two with 
hemoglobinopathy E, two women with heterozygous sickle 
cell anemia, and one with homozygous sickle cell anemia. 
Pregnant women with sickle cell anemia were excluded from 
the analysis due to negative hematological parameters. IDA 
was identified in 89 women (89/829; 10.7%) and anemia 
of other etiology in 62 (62/829; 7.5%). The median CRP 
in IDA was 2 mg/L (0–69) and that in women with other 
anemia 11 mg/L (0–206). There were 654 pregnant women 
without anemia and with the negative inclusion criteria 
(654/829; 78.9%).
The sensivity, specificity, PPV, NPV, and Youden’s 
index of different cut-off levels in nonanemic as well in 
anemic women for MCV are shown in Table 2, for MCH in 
Table 3 and for MRC in Table 4. On the basis of these results, 
the optimal cut-off level for identification of nonsickling 
hemoglobinopathies in nonanemic pregnant women as well 
in women with anemia for other reasons was MCV 80 fL, 
MCH 27.5 pg, or MRC 3%. A receiver operating char-
acteristic curve for nonanemic women is shown in Figure 1. 
The combination of two parameters does not improve the 
sensitivity and specificity.
By using MCH 25 pg, we correctly identified 79.2% of 
women with nonsickling hemoglobinopathies, and by using 
MCV 75 fL only 66.7%. An analysis using receiver operat-
ing characteristic curves and the calculated Youden’s index 
Table 1 The hematological data of the four groups – group 1: nonsickling hemoglobinopathies (24); group 2: IDa (89); group 3: anemia 
of other etiology (62); group 4: normal (654)
Group 1 Group 2 Group 3 Group 4
Mean (SD) Range Mean (SD) Range Mean (SD) Range Mean (SD) Range
Hb (g/l) 112 (14.2) 75–147 101 (7.0) 74–109 104 (6.3) 83–109 125 (8.7) 110–158
rBc (×106/µl) 4.8 (0.5) 3.7–5.9 3.6 (0.3) 3.0–4.5 3.5 (0.3) 2.7–4.6 4.1 (0.4) 2.8–7.1
HcT (%) 33.9 (4.1) 24–43 29.8 (2.0) 23–34 29.9 (1.7) 25–32 35.9 (2.6) 30–49
McV (fl) 71 (6.0) 59–82 83 (7.4) 66–98 87 (5.9) 69–109 87 (4.5) 69–105
McH (pg) 24 (2.3) 20–28 28 (3.0) 21–35 30 (2.5) 22–38 31 (1.9) 21–37
Median Range Median Range Median Range Median Range
Mrc (%) 18.6 2.5–59 1.8 0.1–35 0.9 0.1–27 0.6 0–10
Hrc (%) 7.6 0.3–15 2.8 0.1–36 0.6 0.1–16 0.2 0–11
Ferritin (µg/l) 50 5–533 8 2–20 46 21–192
Note: Parameter was not determined in this group.
Abbreviations: Hb, hemoglobin; HCT, hematocrit; IDA, iron deficiency anemia; MCH, mean corpuscular hemoglobin; MCV, mean corpuscular volume; MRC, microcytosis; 
Hrc, hypochromic erythrocytes; rBc, red blood cell; sD, standard deviation.
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showed that MCV 76 fL, MCH 24 pg, or MRC 10% 
are the optimal cut-off levels for differentiation nonsickling 
hemoglobinopathies among women with concomitant IDA. 
MCH 24 pg had a sensitivity of 75% and a specificity of 
91% (Youden’s index 83.0%; Table 3), MCV 76 fL had 
a sensitivity of 75.0% and a specificity of 78.6% (Youden’s 
index 76.8%; Table 2), and MRC 10% had a sensitivity of 
70.8% and a specificity of 84.3% (Youden’s index 77.6%; 
Table 4). On the basis of our results, the algorithm of tar-
geted antenatal nonsickling hemoglobinopathy screening is 
shown in Figure 2.
Discussion
The present study evaluates the sensitivity and the specificity of 
RBC parameters with different cut-off levels for targeted ante-
natal nonsickling hemoglobinopathy screening. On the basis 
of our results, the optimal cut-off level in nonanemic women 
and in women with anemia for other reasons are MCV 80 fL, 
MCH 27.5 pg, or MRC 3%; and in women with IDA, the 
values are MCV 76 fL, MCH 24 pg, or MRC 10%. The 
combination of two parameters does not improve the sensitivity 
and specificity. The sensitivity and specificity vary depending 
on the type of nonsickling hemoglobinopathy. Hence, MCV 
75 fL was indicative in 100% of women with β-thalassemia, 
whereas it was indicative only in 53.3% of women with 
α-thalassemia. On the other hand, using lower cut-off levels, 
ie, MCV 77 fL or MCH 26 pg, the explicit decrease of the 
sensitivity was assessed among nonanemic women.
The prevalence of nonsickling hemoglobinopathies 
among all women was 3.3% (27/829). Only one study 
described the prevalence of nonsickling hemoglobinopathy 
in Switzerland.5 In contrast to this study, a three-fold higher 
prevalence was determined in our study. The reason for 
this increase is a change in the population due to migration; 
namely, an increased number of refugees and asylum seek-
ers from former Yugoslavia and other developing countries. 
Apart from Luxembourg and Liechtenstein, Switzerland with 
20.6% has the highest rate of migrants among the general 
population in Western Europe.12
To our surprise, half of the pregnant women with nonsick-
ling hemoglobinopathies were nonanemic. Mild anemia with 
Hb 100 g/L was observed in only 16.7% (1/6) of women 
with heterozygous α-thalassemia, in 66.6% (6/9) of women 
Table 2 Specificity, sensitivity, PPV, NPV, and Youden’s index 
of different cut-off levels for McV in (a) nonanemic pregnant 
women and (b) women with IDa
MCV,  
fL
Sensitivity Specificity PPV NPV Youden’s 
index, %
(a)
 75 66.7 99.2 76.2 98.8 65.9
 76 75.0 99.1 78.3 99.1 74.1
 77 75.0 98.6 66.7 99.1 73.6
 78 87.5 98.0 61.8 99.5 85.5
 79 91.7 97.1 53.7 99.7 88.8
 80 95.8 95.4 43.4 99.8 91.2
 81 95.8 93.9 36.5 99.8 89.7
(b)
 74 66.7 86.5 57.1 90.6 76.6
 75 66.7 82.0 50.0 90.1 74.4
 76 75.0 78.6 48.7 92.1 76.8
 77 75.0 75.3 45.0 91.8 75.2
Note: results expressed in %.
Abbreviations: IDA, iron deficiency anemia; MCV, mean corpuscular volume; 
nPV, negative predictive value; PPV, positive predictive value.
Table 3 Specificity, sensitivity, PPV, NPV, and Youden’s index 
of different cut-off levels for McH in (a) nonanemic pregnant 
women and (b) women with IDa
MCH, pg Sensitivity Specificity PPV NPV Youden’s 
index, %
(a)
 25 79.2 99.2 79.2 99.2 78.4
 26 79.1 97.9 57.6 99.2 77.0
 27 87.5 96.3 46.7 99.5 83.8
 27.5 95.8 94.9 41.1 99.8 90.7
 28 95.8 91.3 28.8 99.8 87.1
(b)
 23 54.2 95.5 76.5 88.5 74.9
 24 75.0 91.0 69.2 93.1 83.0
 25 79.2 83.2 55.9 93.7 81.2
 26 79.2 71.9 43.2 92.8 75.6
Note: results expressed in %.
Abbreviations: IDA, iron deficiency anemia; MCH, mean corpuscular hemoglobin; 
nPV, negative predictive value; PPV, positive predictive value.
Table 4 Specificity, sensitivity, PPV, NPV, and Youden’s index 
of different cut-off levels for Mrc in (a) nonanemic pregnant 
women and (b) women with IDa
MRC, % Sensitivity Specificity PPV NPV Youden’s 
index, %
(a)
 3 95.8 94.4 40.4 99.8 90.2
 5 75.0 98.1 60.0 99.1 73.1
 10 70.8 99.5 85.0 99.0 70.3
 15 58.3 99.8 93.3 98.5 58.1
(b)
 3 95.8 58.4 38.3 98.1 77.1
 5 75.0 73.0 42.9 91.6 74.0
 10 70.8 84.3 54.9 91.5 77.6
 15 58.3 89.9 60.9 88.9 74.1
Note: results expressed in %.
Abbreviations: IDA, iron deficiency anemia; MRC, microcytosis; NPV, negative 
predictive value; PPV, positive predictive value.
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with homozygous α-thalassemia, and in 50% (3/6) of women 
with heterozygous β-thalassemia. That means that if we only 
screen anemic women in pregnancy, we miss a huge group of 
women who are at risk. Therefore, laboratory diagnosis should 
be performed in all women with positive RBC indices regard-
less of hemoglobin and iron status. Using these parameters we 
can identify a huge group of individuals who are carriers of 
Figure 1 receiver operating characteristic curves of the three parameters for 
nonsickling hemoglobinopathy screening among nonanemic women.
Abbreviations: McH, mean corpuscular hemoglobin; McV, mean corpuscular 
volume; Mrc, microcytosis.
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α- or β-thalassemia. However, as some women have normal 
red cell indices, it is impossible to detect all women by screen-
ing on the basis of the full blood count alone. Because of false 
positivity of red cell indices due to iron deficiency,13–15 differ-
ent cut-off levels are used in nonanemic and anemic women. 
In women with IDA and MCV 76 fL, MCH 24 pg, or 
MRC 10%, the laboratory analysis is recommended because 
iron deficiency potentially masks hemoglobinopathy. It might 
be useful to correct iron deficiency before performing HPLC 
or molecular diagnostics.
The limitation of our study is the lack of HPLC and 
molecular analysis in all women. However, in a country 
with a low prevalence of hemoglobin disorders, conducting 
universal screening would not be cost effective. The choice 
of the screening method is based on cost-effectiveness, and 
it has been demonstrated that at a prevalence of at least 
16 sickle cell traits/1,000 there is no significant cost differ-
ence between universal and targeted screening programs. 
Therefore, targeted antenatal screening is recommended in 
Switzerland. However, as a result of our study, we presume 
the difference of the prevalence between prevalence in the 
country and in the big city. Zurich with the prevalence of 
3.3% belongs to the high-prevalence areas. Therefore, like 
in Belgium, the universal antenatal screening should be 
limited to the big cities in the future. The second debatable 
point is the cut-off level of serum ferritin. In the literature, 
the cut-off level of serum ferritin varies between 10 µg/L and 
20 µg/L.11,12 Because we saw high intraindividual variations 
between 10 µg/L and 20 µg/L, we chose ferritin 20 µg/L 
as the cut-off level.
Figure 2 The algorithm of targeted antenatal nonsickling hemoglobinopathy screening.
Abbreviations: HPlc, high-performance liquid chromatography; McH, mean corpuscular hemoglobin; McV, mean corpuscular volume.
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The impact of antenatal screening programs is generally 
assessed by the uptake of prenatal diagnosis, optimal 
management, care, and termination of affected pregnancies.16–18 
Therefore, four European countries with high prevalence of 
hemoglobinopathy have adopted a universal neonatal screen-
ing program financed by the authorities in public health 
(England, France, Belgium, and recently, the Netherlands) 
and one country (Portugal) has adopted an antenatal univer-
sal screening.5,19 Since the discovery of cell-free fetal DNA 
in maternal plasma, the noninvasive prenatal assessment of 
hemoglobinopathies has been achieved.20
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